Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial
We demonstrate a significant reduction in residual proteinuria in patients with inactive LN with dapagliflozin without safety concerns.
Authors
- Paula Sandrin‐Garcia (ORCID: https://orcid.org/0000-0003-4641-7429)
- Camila Barbosa Lyra de Oliveira (ORCID: https://orcid.org/0000-0003-2080-923X)
- Gisele Vajgel (ORCID: https://orcid.org/0000-0002-2606-3638)
- Lucila Maria Valente (ORCID: https://orcid.org/0000-0003-2908-4212)
- Camilla Albertina Dantas de Lima (ORCID: https://orcid.org/0000-0003-0320-3674)
- Denise Maria do Nascimento Costa (ORCID: https://orcid.org/0000-0001-7306-7044)
- Carlos Rezende Filho
- Braziliano Júnior
Institutions
- Universidade Federal de Pernambuco (BR)
- Instituto Federal de Educação, Ciência e Tecnologia de Pernambuco (BR)
- Hospital das Clínicas da Universidade Federal de Pernambuco (BR)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1093/ndt/gfaf257
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00